Papillomavirus-like particles and HPV vaccine development

Seminars in Cancer Biology

Volumn 7, Issue 6, 1996, Pages 373-382

  Schiller, John T ^a   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibodies; Cervical cancer; Papillomaviruses; Vaccine; Virus like particles

Indexed keywords

CANCER VACCINE; CAPSID PROTEIN; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL MODEL; ANTIBODY RESPONSE; DRUG FORMULATION; GENITAL TRACT INFECTION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PAPILLOMA VIRUS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

EID: 0030419902     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1996.0046     Document Type: Review

References (65)

1. 1. IARC (1995) Human Papillomaviruses, Vol. 64, pp 277-282. WHO
2. 2. Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55:891-903
3. 3. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH (1994) Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 271:1866-1869
4. 4. Tindle RW, Frazer IH (1994) Immune response to human papillomavirues and the prospects for human papillomavirus-specific immunization. Curr Top Microbiol Immunol 186:217-253
5. 5. Wu TC (1994) Immunology of the human papillomavirus in relation to cancer. Curr Opin Immunol 6:746-754
6. 6. Schiller JT, Okun M (1996) Papillomavirus vaccines: current status and future prospects. Adv Dermatol 11:355-380
7. 7. Steller MA, Schiller JT (1996) Human papillomavirus immunology and vaccine prospects. J Natl Cancer Inst Mono 21:145-148
8. 8. Robbins JB, Schneerson R, Szu SC (1995) Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171:1387-1398
9. 9. Jarrett WFH, O'Neill BW, Gaukroger JM, Smith KT, Laird HM, Campo MS (1990) Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec 126:473-475
10. 10. Shope RE (1935) Immunization of rabbits to infectious papillomatosis. J Exp Med 65:219-231
11. 11. Kidd JG (1938) The course of virus-induced rabbit papillomas as determined by virus, cells, and host. J Exp Med 67:551-574
12. 12. Jin XW, Cowsert L, Marshall D, Reed D, Pilacinski W, Lim LY, Jenson AB (1990) Bovine serological response to a recombinant BPV-1 major capsid protein vaccine. Intervirology 31:345-354
13. 13. Pilacinski WP, Glassman DL, Glassman KF, Reed DE, Lum MA, Marshall RF, Muscoplat CC, Faras AJ (1986) Immunization against bovine papillomavirus infection. Papillomaviruses: Ciba Foundation Symposium 120, pp 136-156. Wiley, Chichester
14. 14. Ghim S, Christensen ND, Kreider JW, Jenson AB (1991) Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int J Cancer 49:285-289
15. 15. Hagensee M, Galloway D (1993) Growing human papillomaviruses and virus-like particles in the laboratory. Papillomavirus Rep 4:121-124
16. 16. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-12184
17. 17. Lowy DR, Kirnbauer R, Schiller JT (1994) Genital human papillomavirus infection. Proc Natl Acad Sci USA 91:2436-2440
18. 18. Hagensee ME, Yaegashi N, Galloway DA (1993) Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315-322
19. 19. Kirnbauer R, Taub J, Greenstone H, Roden RBS, Durst M, Gissmann L, Lowy DR, Schiller JT (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67:6929-6936
20. 20. Muller M, Gissmann L, Cristiano RJ, Sun XY, Fraser IH, Jenson AB, Alonso A, Zentgraf H, Zhou J (1995) Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol 69:948-954
21. 21. Rose RC, Reichman RC, Bonnez W (1994) Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75:2075-2079
22. 22. Christensen ND, Hopfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, Budgeon LR, Reed CA, Kreider JW (1994) Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75:2271-2276
23. 23. Le Cann P, Coursaget P, Iochmann S, Touze A (1994) Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett 117:269-274
24. 24. Roden RBS, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT (1995) Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 69:5147-5151
25. 25. Volpers C, Schirmacher P, Streeck RE, Sapp M (1994) Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 200:504-512
26. 26. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT (1996) Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70:3298-3301
27. 27. Heino P, Dillner J, Schwartz S (1996) Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology 214:349-359
28. 28. Roden RBS, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT (1996) In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 70:5875-5883
29. 29. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M (1995) Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206:126-135
30. 30. Hofmann KJ, Neeper MP, Markus HZ, Brown DR, Muller M, Jansen KU (1996) Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J Gen Virol 77:465-468
31. 31. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR (1995) Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:3959-3963
32. 32. Christensen ND, Reed CA, Cladel NM, Han R, Kreider HW (1996) Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomaviruses. J Virol 70:960-965
33. 33. Kirnbauer R, Chandrachud L, O'Neil B, Wagner E, Grindlay G, Armstrong A, McGarvie G, Schiller J, Lowy D, Campo M (1996) Virus-like particles of Bovine Papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37-44
34. 34. Suzich JA, Ghim S, Palmer-Hill FJ, White WI, Tamura JK, Bell J, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553-11557
35. 35. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R (1994) A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62:194-198
36. 36. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA (1990) Monoclonal antibody mediated neutralization of infectious human papillomavirus type 11. J Virol 64:5678-5681
37. 37. Smith LH, Foster C, Hitchcock ME, Leiserowitz GS, Hall K, Isseroff R, Christensen ND, Kreider JW (1995) Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol 105:438-444
38. 38. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184
39. 39. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St Louis ME, Han C, Svare EI, Kruger Kjaer S, Lowy DR, Schiller JT (1995) Divergent Human Papillomavirus type 16 variants are serologically cross-reactive. J Infectious Dis 172:1584-1587
40. 40. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT (1994) A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86:494-499
41. 41. Schiller JT, Roden RBS (1996) Papillomavirus-like particles: basic and applied studies, in Papillomavirus Reviews: Current Research on Papillomaviruses (Lacey C, ed.) pp. 101-112. Leeds Medical Information, Leeds
42. 42. Ghim S, Young R, Jenson AB (1996) Antigenicity of bovine papillomavirus type 1 (BPV-1) virus-like particles compared with that of intact BPV-1 virions. J Gen Virol 77:183-188
43. 43. Zhou J, Sun XY, Louis K, Frazer IH (1994) Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J Virol 68:619-625
44. 44. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide prospective. J Natl Cancer Inst 87:796-802
45. 45. Barrasso R (1992) HPV-related genital lesions in men, in The Epidemiology of Cervical Cancer and Human Papillomavirus (Munoz N, Bosch FX, Shah KV, Meheus A, eds), pp 85-92. International Agency for Research on Cancer, Lyon
46. 46. Greer CE, Wheeler CM, Lander MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TSB, Ralston R (1995) Human papillomavirus (HPV) type distribution and serological response to HPV 6 virus-like particle in patients with genital warts. J Clin Microb 33:2058-2063
47. 47. Ashley RL, Corey L, Dalessio J, Wilson P, Remington M, GB, Trethewey P (1994) Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infection. J Infect Dis 170:20-26
48. 48. Bouvet JP, Belec L, Pires R, Pillot J (1994) Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infection Immun 62:3957-3961
49. 49. Wu HY, Nikolova EB, Beagley KW, Eldridge JH, Russell MW (1997) Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization. Infect Immun 65:227-235
50. 50. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA (1996) The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174:927-936
51. 51. Brinton LA (1992) Epidemiology of cervical cancer-overview, in The Epidemiology of Human Papillomavirus and Cervical Cancer (Munoz N, Bosch FX, Shah KV, Meheus A, eds). International Agency of Research on Cancer, Lyon
52. 52. Cason J, Kaye JN, Best JM (1996) Evidence for the transmission of human genital papillomavirus by non-sexual routes, in Papillomavirus Reviews: Current Research on Papillomaviruses (Lacey C, ed.) pp 281-289. Leeds Medical Information, Leeds, England
53. 53. Lorincz AT (1996) Molecular methods for the detection of human papillomavirus. Ostet Gynecol Clin North Am 23:707-730
54. 54. Schiffman MH, Brinton LA (1995) The epidemiology of cervical carcinogenesis. Cancer 76:1888-1901
55. 55. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ (1992) Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 79:328-337
56. 56. Ulmer JB, Deck RR, Yawman A, Freidman A, Dewitt C, Martinez D, Montgomery DL, Donnelly JJ, Lie MA (1996) DNA vaccines for bacteria and viruses. Adv Exp Med Bio 397:49-53
57. 57. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA (1996) Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 173:314-320
58. 58. Teich N, Wyke J, Kaplan P (1985) Pathogenesis of retrovirus-induced disease, in RNA Tumor Viruses (Weiss R, Teich N, Varmus H, Coffin J, eds) 2 edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
59. 59. Paoletti E (1996) Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 93:11349-11353
60. 60. Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:11341-11348
61. 61. Hopkins S, Kraehenbuhl J-P, Schoddel F, Potts A, Peterson D, De Grandi P, Nardelli-Haefliger D (1995) A combination Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 63:3279-3286
62. 62. Schodel F, Curtiss R (1995) Salmonellae as oral vaccine carriers. Dev Biol Stand 84:245-253
63. 63. Mason HS, Lam DM-K, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 89:11745-11749
64. 64. Mason HS, Ball JM, Shi J-J, Estes MK, Arntzen CJ (1996) Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 93:5335-5340
65. 65. Bachmann MF, Zinkernagel RM (1996) The influence of virus structure on antibody responses and virus serotype formation. Immun Today 17:553-558